Esteban Gomez
Pediatric Hematology-Oncology · Orange, CANPI 1992900641
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by CSL Behring at 29.2% of the total. Reporting peaked in 2022 at $18,956 and has fallen 82.5% since, to $3,312 in 2025. Among pediatric hematology-oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $482.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$16K
- Sanofi$16K
- Global Blood Therapeutics, Inc.$8K
- Genentech USA, Inc.$6K
- Bayer$2K
- Chiesi USA, Inc.$2K
- plus $4K from 16 others
Across 53 payments — averaging $4057.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bioverativ Therapeutics Inc.$157K
- Sanofi US Services Inc.$47K
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- Shire North American Group Inc$3K
What the payments were for
- Consulting fees$26,36547%
- Speaking & faculty fees$21,91439%
- Travel & lodging$4,3498%
- Food & beverage$2,8145%
- Education$660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 20 | $16,205 |
| Sanofi | 22 | $15,698 |
| Global Blood Therapeutics, Inc. | 13 | $8,429 |
| Genentech USA, Inc. | 6 | $6,464 |
| Bayer | 4 | $2,277 |
| Chiesi USA, Inc. | 3 | $2,130 |
| Alnylam Pharmaceuticals Inc. | 2 | $1,535 |
| Novartis | 8 | $1,346 |
| Biomarin Pharmaceutical Inc. | 7 | $269 |
| AstraZeneca | 1 | $175 |
| Spark Therapeutics, Inc. | 3 | $165 |
| Novo Nordisk | 5 | $132 |
| Genentech, Inc. | 4 | $127 |
| Portola Pharmaceuticals, LLC | 1 | $125 |
| Agios Pharmaceuticals, Inc. | 5 | $121 |
| HEMA Biologics, LLC | 2 | $86 |
| Pfizer | 3 | $56 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $56 |
| Vertex | 2 | $40 |
| Boston Scientific | 1 | $28 |
| Bio Products Laboratory USA, Inc. | 1 | $23 |
| Genetix Biotherapeutics Inc | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,508 in reported general payments places this provider in the 90th percentile of 307 pediatric hematology-oncology providers in California.
See all pediatric hematology-oncology providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TavalisseFostamatinib Disodium | 12 | $179,595 |
| Deferasirox | 52 | $123,754 |
| XareltoRivaroxaban | 17 | $24,529 |
Paid to pharmacies, not to this prescriber.
Other pediatric hematology-oncology in Orange
- Vanessa Salinas-LunaOrange$344K
- Arash MahajerinOrange$249K
- Amit SoniOrange$70K
- Diane NugentOrange$55K
- van HuynhOrange$37K
- Mariko SatoOrange$21K
- Philip PizzoPalo Alto$2.6M
- Vinod BalasaMadera$508K
- Akshat JainRedlands$447K
- Noah FedermanLos Angeles$399K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.